文献速递性腺与生殖内分泌骨质疏松与钙磷/甲状旁腺

地舒单抗对重度少精症男性精子浓度的影响:一项随机对照试验

Effect of Denosumab on Sperm Concentration in Men With Severe Oligospermia: A Randomized Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

这项双盲、安慰剂对照、单中心随机对照试验纳入42例少精症男性,按2:1随机接受单次皮下注射地舒单抗60 mg(n=28)或安慰剂(n=14),观察80天。第80天时,两组精子浓度与精子总数均无差异,睾酮、LH、FSH、抑制素B及AMH亦无差异;两组从基线到第80天精子浓度和精子总数均升高,但抑制素B未升高。结论:地舒单抗未改善精子浓度,也未改变生殖激素。

要点

  • 地舒单抗60 mg单次皮下注射未改善重度少精症男性第80天精子浓度。
  • 地舒单抗组与安慰剂组的睾酮、LH、FSH、抑制素B、AMH均无差异。
  • 两组精子浓度和精子总数较基线均升高,但抑制素B未升高。

核心结论

  • 地舒单抗与安慰剂相比未改善精子浓度,也未改变生殖激素。
  • 地舒单抗不优于接受维生素D和钙补充的安慰剂组男性。

研究设计与样本

  • 双盲、安慰剂对照、单中心随机对照试验,纳入42例少精症男性,主要终点为精子浓度改善。
  • 按2:1随机接受单次皮下注射地舒单抗60 mg(n=28)或安慰剂(n=14),观察80天。

主要发现

  • 第80天地舒单抗组与安慰剂组精子浓度无差异。
  • 第80天两组精子总数无差异。
  • 两组血清睾酮、LH、FSH、抑制素B、AMH均无差异。
  • 两组从基线到第80天精子浓度和精子总数均升高,但血清抑制素B未升高。

临床怎么用

  • 对重度少精症男性,单次地舒单抗60 mg未显示改善精子浓度的作用,不应以提升精子浓度为目的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: RANKL has been suggested as a novel regulator of male reproduction, and a recent randomized controlled trial (RCT) showed that the RANKL-inhibitor denosumab, normally used to treat osteoporosis, can improve semen quality in infertile men with high anti-Müllerian hormone (AMH) and small testicles. Therefore, this RCT aimed to investigate the effect of denosumab in men with severe oligospermia prospectively selected by serum AMH and testicular size. MATERIALS AND METHODS: A double-blinded, placebo-controlled, single-center RCT, including 42 men with oligospermia with the main endpoint of improving sperm concentration. The groups were randomized 2:1 to receive either a single subcutaneous injection of denosumab 60 mg (n = 28) or a placebo treatment (n = 14) for 80 days. RESULTS: Thirty-nine men completed the study, with 26 assigned to the denosumab group and 13 to the placebo group. No differences in sperm concentration or total sperm count were found at day 80 between those treated with denosumab or placebo. Additionally, there were no differences in serum testosterone, LH, FSH, inhibin B, or AMH. Men treated with denosumab or placebo experienced an increase in both sperm concentration and total sperm count but not serum inhibin B from baseline to day 80. CONCLUSION: This RCT showed that denosumab did not improve sperm concentration or alter reproductive hormones compared to placebo. Denosumab is not superior to the vitamin D- and calcium-supplemented men in the placebo group.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yahyavi SK, Jorsal MJ, Wulff SM, et al. Effect of Denosumab on Sperm Concentration in Men With Severe Oligospermia: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2026. PMID: 40858297. doi:10.1210/clinem/dgaf481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。